- Home
- ACIU vs ACR Comparison
ACIU vs ACR Comparison
Compare ACIU & ACR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- ACR
- Stock Information
- Founded
- ACIU 2003
- ACR 2005
- Country
- ACIU Switzerland
- ACR United States
- Employees
- ACIU N/A
- ACR N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- ACR Real Estate Investment Trusts
- Sector
- ACIU Health Care
- ACR Real Estate
- Exchange
- ACIU Nasdaq
- ACR Nasdaq
- Market Cap
- ACIU 168.7M
- ACR 139.0M
- IPO Year
- ACIU 2016
- ACR N/A
- Fundamental
- Price
- ACIU $1.73
- ACR $18.17
- Analyst Decision
- ACIU Strong Buy
- ACR Buy
- Analyst Count
- ACIU 2
- ACR 2
- Target Price
- ACIU $10.00
- ACR $17.50
- AVG Volume (30 Days)
- ACIU 103.2K
- ACR 33.2K
- Earning Date
- ACIU 08-05-2025
- ACR 07-30-2025
- Dividend Yield
- ACIU N/A
- ACR N/A
- EPS Growth
- ACIU N/A
- ACR N/A
- EPS
- ACIU N/A
- ACR 0.34
- Revenue
- ACIU $32,014,254.00
- ACR $83,545,000.00
- Revenue This Year
- ACIU N/A
- ACR $3.57
- Revenue Next Year
- ACIU $533.21
- ACR N/A
- P/E Ratio
- ACIU N/A
- ACR $52.23
- Revenue Growth
- ACIU 91.20
- ACR 6.92
- 52 Week Low
- ACIU $1.43
- ACR $12.45
- 52 Week High
- ACIU $4.98
- ACR $23.81
- Technical
- Relative Strength Index (RSI)
- ACIU 54.55
- ACR 44.37
- Support Level
- ACIU $1.60
- ACR $17.86
- Resistance Level
- ACIU $1.82
- ACR $19.24
- Average True Range (ATR)
- ACIU 0.10
- ACR 0.62
- MACD
- ACIU 0.01
- ACR -0.02
- Stochastic Oscillator
- ACIU 65.38
- ACR 26.77
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About ACR ACRES Commercial Realty Corp.
ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralize debt obligations, and private equity investments mainly issued by financial institutions.